Pillar · Neuroscience research
Cognitive and Neuroactive Peptide Research
Neuroactive peptide research examines sequences that influence neurotrophic signalling, monoamine systems and stress-response pathways. The defining constraint is the blood-brain barrier; the defining limitation of the evidence base is that much of the human literature for the best-known compounds was published in a single region and is not well represented in international randomised trials.
Evidence position
Early laboratory research
Research evidence, established clinical evidence and regulatory approval are three different things. This page distinguishes them throughout and does not present research compounds as approved treatments.
The delivery problem
The blood-brain barrier excludes most peptides. Research therefore relies on intranasal administration exploiting olfactory and trigeminal pathways, on fragments small enough to use transporters, or on peripheral signalling that indirectly influences central pathways. Any claim of central activity should specify how the compound is proposed to reach the brain.
BDNF and neurotrophic signalling
Much of this literature reports changes in brain-derived neurotrophic factor expression, which supports synaptic plasticity and neuronal survival. BDNF change is a mechanistic marker, not a cognitive outcome; exercise produces the same directional change, and the relationship between BDNF and measured cognition in humans is inconsistent.
Why the evidence looks stronger than it is
Semax and Selank are frequently described as clinically established. The underlying human studies are largely older, small, and published outside the international randomised-trial system, often without pre-registration or independent replication. That is not proof of absence of effect, but it is not equivalent to a modern controlled evidence base either.
Compounds studied in this area
| Compound | What it is | Evidence tier |
|---|---|---|
| Semax | An ACTH(4-10) analogue studied in neurotrophic and attention-related models. | Early laboratory research |
| Selank | A tuftsin analogue studied in anxiety-related and immunomodulatory research. | Early laboratory research |
| Neuroprotective fragments | Short sequences studied in ischaemia and excitotoxicity models. | Early laboratory research |
Comparisons in this cluster
Key takeaways
- Neuroactive peptide research examines sequences that influence neurotrophic signalling, monoamine systems and stress-response pathways. The defining constraint is the blood-brain barrier; the defining limitation of the evidence base is that much of the human literature for the best-known compounds was published in a single region and is not well represented in international randomised trials.
- Overall evidence position for this topic: early laboratory research.
- Findings in cells or animals are hypotheses about humans, never demonstrations in humans.
- Nothing on this page is medical advice, a protocol, or a dosing recommendation.
Frequently asked questions
Do cognitive peptides improve memory?
There is no robust controlled human evidence that the peptides in this category improve memory in healthy adults. Most reported findings are mechanistic or from small, regionally concentrated studies.
How would a peptide reach the brain?
Chiefly via intranasal delivery along olfactory and trigeminal routes, since most peptides do not cross the blood-brain barrier from systemic circulation.
Continue reading
Related research hubs
Peptide Science
How peptides are built, how they signal, how they are synthesised and how they are studied — the foundational science behind every other topic on this site.
Peptide Research & Clinical Trials
How peptide research is conducted and graded — trial phases, endpoints, evidence hierarchy, and how to read a peptide study without over-reading it.
Peptide Safety
What is actually known about peptide safety — immunogenicity, contamination, unknown long-term profiles, and why absence of reported harm is not evidence of safety.
About this page
Written and reviewed by the Peptide Intel Hub Editorial Team. Last reviewed 8 September 2026.
Scientific disclaimer: this page is educational and does not constitute medical advice. Research compounds referenced here are not approved treatments. See our research disclaimer.